Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00509301 · ClinicalTrials.gov registry record · Phase 1
Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme
A Phase 1 study, sponsored by Peregrine Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00509301 is a Phase 1 study that has completed, run by Peregrine Pharmaceuticals. The registered enrollment target is 12 participants.
The verdict
NCT00509301, a Phase 1 study, has completed, sponsored by Peregrine Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
RATIONALE: Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody. This monoclonal antibody is designed to bind tumor cells and deliver radiation directly to the center of the tumor mass while minimizing effects on normal tissues. Cotara® thus literally destroys the tumor "from the inside out." This may be an effective treatment for glioblastoma multiforme, a malignant type of brain cancer. PURPOSE: This trial is studying the safety and radiation distribution of Cotara® in patients with recurrent glioblastoma multiforme.
Interventions
- DRUG 131-I-chTNT-1/B MAB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-11 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00509301
The ClinicalTrials.gov registry entry for NCT00509301 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Peregrine Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 131-I-chTNT-1/B MAB is the first listed.
NCT00509301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00509301 about?
NCT00509301 is a clinical study titled "Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme". RATIONALE: Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody. This monoclonal antibody is designed to bind tumor cells and deliver radiation directly to the center of the tumor mass while minimizing effects on normal tissues. Cot...
What is the current status of trial NCT00509301?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2006-11. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00509301?
The interventions under investigation include: 131-I-chTNT-1/B MAB (DRUG).
Who is sponsoring clinical trial NCT00509301?
This trial is sponsored by Peregrine Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.